Company profile: ProfoundBio
1.1 - Company Overview
Company description
- Provider of antibody-based cancer therapeutics, including antibody-drug conjugates. Clinical-stage pipeline includes Rina-S, a folate receptor alpha-targeting ADC for ovarian and other solid tumors (Phase 2); PRO1160, a CD70-targeting ADC for solid tumors and hematological malignancies (Phase 1/2); PRO1107, a PTK7-targeted ADC with a hydrophilic MMAE-based linker-drug (Phase 1/2); and PRO1286, a bispecific EGFR/cMET ADC (trials anticipated in 2024).
Products and services
- PRO1107: Hydrophilic-linker-enabled PTK7-targeted ADC incorporating a novel MMAE-based linker-drug, in Phase 1/2 clinical trials for advanced solid tumors
- PRO1160: Custom-engineered ADC targeting CD70 across various solid tumors and hematological malignancies, currently in Phase 1/2 clinical trials
- Rinatabart Sesutecan (Rina-S): Clinical-stage ADC targeting folate receptor alpha for treating ovarian and other solid tumors, currently advancing through Phase 2 clinical trials
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProfoundBio
Epigenomics
HQ: Germany
Website
- Description: Provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epigenomics company profile →
Tempest Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics that modulate anti-tumor pathways, including TPST-1120, an oral PPARα antagonist designed to inhibit fatty acid oxidation and inflammation with potential in hepatocellular, renal cell, and cholangiocarcinoma, and TPST-1495, an oral dual EP2/EP4 antagonist in Phase 1/1b combination studies to reduce tumor growth and immune suppression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tempest Therapeutics company profile →
Insure One
HQ: United States
Website
- Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insure One company profile →
VelosBio
HQ: United States
Website
- Description: Provider of clinical-stage, next-generation oncology therapeutics, developing first-in-class ROR1-directed treatments, including novel antibody-drug conjugates for hematologic and solid tumors; offerings include injection-based therapies such as WINREVAIR (sotatercept-csrk) and KEYTRUDA (pembrolizumab).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VelosBio company profile →
Silverback Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing ImmunoTAC treatments targeting previously inaccessible disease pathways, and a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silverback Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProfoundBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProfoundBio
2.2 - Growth funds investing in similar companies to ProfoundBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProfoundBio
4.2 - Public trading comparable groups for ProfoundBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →